The guideline defines basic terms, definitions and standard reporting timeframes for expedited reporting. This guideline is intended to help harmonize methods for gathering and evaluating clinical safety data. The guideline also discusses mechanisms for expedited reporting. The guideline is intended to help harmonize methods for gathering and evaluating clinical safety data.

DATES: Effective March 1, 1995. Submit written comments at any time.

ADDRESSES: Submit written comments on the guideline to the Dockets Management Branch (HFA - 305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Copies of the guideline are available from CDER Executive Secretariat, which coordinates the enforcement of these regulations, 11284 Federal Register, Vol. 60, No. 40 / Wednesday, March 1, 1995 / Notices

FOR FURTHER INFORMATION CONTACT: Regarding the guideline: Murray M. Lumpkin, Center for Drug Evaluation and Research (HFD–2), 5600 Fisher Lane, Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote international harmonization of regulatory requirements. FDA has participated in many meetings designed to enhance harmonization and is committed to seeking scientifically based harmonized technical procedures for pharmaceutical development. One of the goals of harmonization is to identify and then reduce differences in technical requirements for drug development among regulatory agencies.

ICH was organized to provide an opportunity for tripartite harmonization initiatives to be developed with input from both regulatory and industry representatives. FDA also seeks input from consumer representatives and others. ICH is concerned with harmonization of technical requirements for the registration of pharmaceutical products among three regions: The European Union, Japan, and the United States. The six ICH sponsors are the European Commission; the International Federation of Pharmaceutical Industry and Associations; the Japanese Ministry of Health and Welfare; the Japanese Pharmaceutical Manufacturers Association; the Centers for Drug Evaluation and Research and Biologics Evaluation and Research, FDA; and the Pharmaceutical Research and Manufacturing of America. The ICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation of Pharmaceutical Manufacturers Association (IFPMA). The ICH Steering Committee includes representatives from each of the ICH sponsors and IFPMA, as well as observers from the World Health Organization, the Canadian Health Protection Branch, and the European Free Trade Area.

Harmonization of clinical safety data management was selected as a priority topic during the early stages of the ICH initiative. In the Federal Register of July 9, 1993 (58 FR 37408), FDA published a draft tripartite guideline entitled, “Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.” The notice gave interested persons an opportunity to submit comments by August 9, 1993.

After consideration of the comments received and revisions to the guideline, a final draft of the guideline was submitted to the ICH Steering Committee and endorsed by the three participating regulatory agencies at the ICH meeting held in October 1994.

The guideline defines basic terms, such as “adverse event,” “adverse drug reaction,” and “unexpected adverse drug reaction.” The guideline also provides guidance on determining whether an adverse drug reaction is expected.” and contains standards for expedited reporting, describing what information should be reported, recommending reporting timeframes and the use of the CIOMS–1 form for reporting information or, alternatively, suggesting that basic information or data elements be used. The guideline also discusses: Whether and when the blind should be broken for a patient; reporting reactions associated with comparison drug or placebo treatments; products with more than one dosage form, route of administration, or use; and adverse events that occur after the patient has completed the clinical study.

In the past, guidelines have generally been issued under § 10.90(b) (21 CFR 10.90(b)), which provides for the use of guidelines to state procedures or standards of general applicability that are not legal requirements but are acceptable to FDA. The agency is now in the process of revising § 10.90(b). Therefore, this guideline is not being issued under the authority of § 10.90(b), and it does not create or confer any rights, privileges, or benefits for or on any person, nor does it operate to bind FDA in any way.

As with all of FDA’s guidelines, the public is encouraged to submit written comments with new data or other new information pertinent to this guideline. The comments in the docket will be periodically reviewed, and where appropriate, the guideline will be amended. The public will be notified of any such amendments through a notice in the Federal Register.

Interested persons may, at any time, submit written comments on the guideline to the Dockets Management Branch (address above). Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guideline and received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday.

The text of the guideline follows:

Clinical Safety Data Management: Definitions and Standards for Expedited Reporting

I. Introduction

It is important to harmonize the way to gather and, if necessary, to take action on important clinical safety information arising during clinical development. Thus, agreed definitions and terminology, as well as procedures, will ensure uniform Good Clinical Practice standards in this area. The initiatives already undertaken for marketed medicines through the CIOMS–1 and CIOMS–2 Working Groups on expedited (alert) reports and periodic safety update reporting, respectively, are important precedents and models. However, there are special circumstances involving medicinal products under development, especially in the early stages and before any marketing
experience is available. Conversely, it must be recognized that a medicinal product will be under various stages of development and/or marketing in different countries, and safety data from marketing experience will ordinarily be of interest to regulators in countries where the medicinal product is still under investigational only (Phase 1, 2, or 3) status. For this reason, it is both practical and well-advised to regard premarketing and postmarketing clinical safety reporting concepts and practices as interdependent, while recognizing that responsibility for clinical safety within regulatory bodies and companies may differ. Depending on the status of the product (investigational versus marketed).

There are two issues within the broad subject of clinical safety data management that are appropriate for harmonization at this time:

1. The development of standard definitions and terminology for key aspects of clinical safety reporting, and

2. The appropriate mechanism for handling expedited (rapid) reporting, in the investigational (i.e., preapproval) phase.

The provisions of this guideline should be used in conjunction with other ICH Good Clinical Practice guidelines.

II. Definitions and Terminology Associated with Clinical Safety Experience

A. Basic Terms

Definitions for the terms adverse event (or experience), adverse reaction, and unexpected adverse reaction have previously been agreed to by consensus of the more than 30 Collaborating Centers of the WHO International Drug Monitoring Centre (Uppsala, Sweden), (Edwards, I. R., et al., “Harmonisation in Pharmacovigilance,” Uppsala, Sweden). (Edwards, I. R., et al., “Harmonisation in Pharmacovigilance,” Drug Safety, 10(2): 93–102, 1994.) Although these definitions can pertain to situations involving clinical investigations, some minor modifications are necessary, especially to accommodate the preapproval, development environment.

The following definitions, with input from the WHO Collaborative Centre, have been agreed.

1. Adverse Event (or Adverse Experience).

An untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

An adverse event (AE) can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

2. Adverse Drug Reaction (ADR).

In the preapproval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established:

All noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions.

The phrase “responses to medicinal products” means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out.

Regarding marketed medicinal products, a well-accepted definition of an adverse drug reaction in the postmarketing setting is found in WHO Technical Report 498 (1972) and reads as follows:

“A response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for modification of physiological function. The term “side effect” has been used in various ways in the past, usually to describe negative (unfavorable) effects, but also positive (favorable) effects. It is recommended that this term no longer be used and particularly should not be regarded as synonymous with adverse event or adverse reaction.

3. Unexpected Adverse Drug Reaction

An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g., Investigator’s Brochure for an unapproved investigational medicinal product). See III.C.

B. Serious Adverse Event Or Adverse Drug Reaction

During clinical investigations, adverse events may occur which, if suspected to be medicinal product-related (adverse drug reactions), might be significant enough to lead to important changes in the way the medicinal product is developed (e.g., change in dose, population, needed monitoring, consent forms). This is particularly true for serious or severe reactions which more severe forms, threaten life or function. Such reactions should be reported promptly to regulators.

Therefore, special medical or administrative criteria are needed to define reactions that, either due to their nature (“serious”) or due to the significant, unexpected information they provide, justify expedited reporting.

To ensure that no confusion or misunderstanding exist of the difference between the terms “serious” and “severe,” which are not synonymous, the following note of clarification is provided:

The term “serious” is often used to describe the intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This is not the same as “serious,” which is based on patient/event outcome action or criteria usually associated with events that pose a threat to a patient’s life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.

After reviewing the various regulatory and other definitions in use or under discussion elsewhere, the following definition is believed to encompass the spirit and meaning of them all:

A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:

1. Results in death

2. Is life-threatening

(NOTE: The term “life-threatening” in the definition of “serious” refers to an event which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.)

• Requires inpatient hospitalization or prolongation of existing hospitalization,

• Results in persistent or significant disability/ incapacity,

• Is a congenital anomaly/birth defect.

Medical and scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the patient or may require intervention to prevent one of the other outcomes listed in the definition above. These should also usually be considered serious.

Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or development of drug dependency or drug abuse.

C. Expectedness of an Adverse Drug Reaction

The purpose of expedited reporting is to make regulators, investigators, and other appropriate people aware of important information on serious reactions. Therefore, such reporting will generally involve events previously unobserved or undocumented, and a guideline is needed on how to define an event as “unexpected” or “expected” (expected/unexpected from the perspective of previously observed, not on the basis of what might be anticipated from the pharmacological properties of a medicinal product).

As stated in the definition (II.A.3.), an “unexpected” adverse reaction is one, the nature or severity of which is not consistent with information in the relevant source documents. Until source documents are amended, expedited reporting is required for additional occurrences of the reaction.

The following documents or circumstances will be used to determine whether an adverse event/reaction is expected:

1. For a medicinal product not yet approved for marketing in a country, a company’s Investigator’s Brochure will serve as the source document in that country. See III.F. and ICH Guideline for the Investigator’s Brochure.

2. Reports which add significant information on specificity or severity of a known, already documented serious ADR constitute unexpected events. For example, an event more specific or more severe than described in the Investigator’s Brochure would be considered “unexpected.” Specific examples would be (a) acute renal failure as a labeled ADR with a subsequent new report of interstitial nephritis and (b) hepatitis with a first report of fulminating hepatitis.

III. Standards for Expedited Reporting

A. What Should Be Reported?

1. Single Cases of Serious, Unexpected ADR’s

All ADR’s that are both serious and unexpected are subject to expedited reporting. This applies to reports from spontaneous sources and from any type of
clinical or epidemiological investigation, independent of design or purpose. It also applies to cases not reported directly to a sponsor or manufacturer (for example, those found in regulatory authority generated ADR registries or in publications). The source of a report (investigation, spontaneous, other) should always be specified.

Expedited reporting of reactions that are serious but expected will ordinarily be inappropriate. Expedited reporting is also inappropriate for serious events from clinical investigations that are considered not related to study product, whether the event is expected or not. Similarly, nonserious adverse reactions, whether expected or not, will ordinarily not be subject to expedited reporting.

Information obtained by a sponsor or manufacturer on serious, unexpected reports from any source should be submitted on an expedited basis to appropriate regulatory authorities if the minimum criteria for expedited reporting can be met. See section III.B.

Causality assessment is required for clinical investigation cases. All cases judged by either the reporting health care professional (sponsor or manufacturer) as having a reasonable suspected causal relationship to the medicinal product qualify as ADR's. For purposes of reporting, adverse event reports associated with marketed drugs (spontaneous reports) usually imply causality.

Many terms and scales are in use to describe the degree of causality (attributability) between a medicinal product and an event, such as certainly, definitely, probably, possibly, or likely related or not related. Phrases such as “plausible relationship,” “suspected causality,” or “causal relationship cannot be ruled out” are also invoked to describe cause and effect. However, there is currently no standard international nomenclature. The expression “reasonable causal relationship” is meant to convey in general use that there are facts (evidence) or arguments that suggest a causal relationship.

2. Other Observations

There are situations in addition to single case reports of “serious” adverse events or reactions that may necessitate rapid communication to regulatory authorities; appropriate medical and scientific judgment should be applied for each situation. In general, information that might materially influence the benefit-risk assessment of a medicinal product or that would be sufficient to consider changes in medicinal product administration or in the overall conduct of a clinical investigation represents such situations. Examples include:

a. For an “expected, serious ADR, an increase in the rate of occurrence which is judged to be clinically important.

b. A significant hazard to the patient population, such as lack of efficacy with a medicinal product used in treating life-threatening disease.

c. A major finding from a newly completed animal study (such as carcinogenicity).

B. Reporting Time Frames

1. Fatal or Life-Threatening Unexpected ADR's

Certain ADR’s may be sufficiently alarming so as to require very rapid notification to regulators in countries where the medicinal product or indication, formulation, or population for the medicinal product are still not approved for marketing, because such reports may lead to reconsideration of suspension of, or other limitations to, a clinical investigation program. Fatal or life-threatening, unexpected ADR’s occurring in clinical investigations qualify for very rapid reporting. Regulatory agencies should be notified (e.g., by telephone, facsimile transmission, or electronic mail) as soon as possible but no later than 7 calendar days after first knowledge by the sponsor that a case qualifies, followed by as complete a report as possible within 8 additional calendar days. This report should include an assessment of the importance and implication of the findings, including relevant previous experience with the same or similar medicinal products.

2. All Other Serious, Unexpected ADR’s

Serious, unexpected reactions (ADR’s) that are not fatal are required to be filed as soon as possible but no later than 15 calendar days after first knowledge by the sponsor that the case meets the minimum criteria for expedited reporting.

3. Minimum Criteria for Reporting

Information for final description and evaluation of a case report may not be available within the required timeframes for reporting outlined above. Nevertheless, for regulatory purposes, initial reports should be submitted within the prescribed time as long as the following minimum criteria are met:

- An identifiable patient: a suspect medicinal product, an identifiable reporting source; and an event or outcome that can be identified as serious and unexpected, and for which, in clinical investigation cases, there is a reasonable suspected causal relationship. Followup information should be actively sought and submitted as it becomes available.

C. How To Report

The CIOMS-I form has been a widely accepted standard for expedited adverse event reporting, and although the format or model used, it is important that certain basic information/data elements, when available, be included with any expedited report, whether in a tabular or narrative presentation. The listing in Attachment 1 addresses those data elements, irrespective of the form or format used, it is important that certain basic information/data elements, whether active comparator drug reactions or similar medicinal products.

E. Miscellaneous Issues

1. Reactions Associated With Active Comparator or Placebo Treatment

It is the sponsor’s responsibility to decide whether active comparator drug reactions should be reported to the other manufacturer and/or directly to appropriate regulatory agencies. Sponsors should report such events to either the manufacturer of the active control or to appropriate regulatory agencies. Events associated with placebo will usually not satisfy the criteria for an ADR and, therefore, for expedited reporting.

2. Products With More Than One Presentation or Use

"Expectedness" may be
product or product-use specific, and separate Investigator’s Brochures may be used accordingly. However, such documents are expected to cover ADR information that applies to all affected product presentations and uses. When relevant, separate discussions of product-specific or use-specific safety information will also be included.

It is recommended that any adverse drug reactions that qualify for expedited reporting observed with one product dosage form or use be cross referenced to regulatory records for all other dosage forms and uses for that product. This may result in a certain amount of overreporting or unnecessary reporting in obvious situations (for example, a report of phlebitis on IV injection sent to authorities in a country where only an oral dosage form is studied or marketed). However, underreporting is completely avoided.

As discussed in the introduction, if expedited reporting is required, the investigator should report the information on a specific report form. This form should be designed to fit the purposes as though they were study reports. Therefore, a causality assessment and determination of expectedness are needed for a decision on whether or not expedited reporting is required.

F. Informing Investigators and Ethics Committees/Institutional Review Boards of New Safety Information

International standards regarding such communication are discussed within the ICH GCP Guidelines, including the addendum on “Guideline for the Investigator’s Brochure.” In general, the sponsor of a study should amend the Investigator’s Brochure as needed, and in accord with any local regulatory requirements, so as to keep the description of safety information updated.

Attachment 1

Key Data Elements for Inclusion in Expedited Reports of Serious Adverse Drug Reactions

The following list of items has its foundation in several established precedents, including those of CIOMS-I, the WHO International Drug Monitoring Centre, and various regulatory authority forms and guidelines. Some items may not be relevant depending on the circumstances. The minimum information required for expedited reporting purposes is: an identifiable patient, the name of a suspect medicinal product, an identifiable reporting source, and an event or outcome that can be identified as serious and unexpected and for which, in clinical investigation cases, there is a reasonable suspected causal relationship. Attempts should be made to obtain followup information on as many other listed items pertinent to the case.

1. Patient Details:
   • Initials,
   • Other relevant identifier (clinical investigation number, for example),
   • Gender,
   • Age and/or date of birth,
   • Weight,
   • Height.

2. Suspected Medicinal Product(s):
   • Brand name as reported,
   • International Nonproprietary Name (INN),
   • Batch number,
   • Indication(s) for which suspect medicinal product was prescribed or tested,
   • Dosage form and strength,
   • Daily dose and regimen (specify units—e.g., mg, mL, mg/kg),
   • Route of administration,
   • Starting date and time of day,
   • Stopping date and time, or duration of treatment.

3. Other Treatment(s):
   • For concomitant medicinal products (including nonprescription/OTC medicinal products) and nonmedicinal product therapies, provide the same information as for the suspected product.

4. Details Of Suspected Adverse Drug Reaction(s):
   • Full description of reaction(s) including body site and severity, as well as the criterion (or criteria) for regarding the report as serious should be given. In addition to a description of the reported signs and symptoms, whenever possible, attempts should be made to establish a specific diagnosis for the reaction.
   • Start date (and time) of onset of reaction,
   • Stop date (and time) or duration of reaction,
   • Dechallenge and rechallenge information,
   • Setting (e.g., hospital, out-patient clinic, home, nursing home),
   • Outcome: Information on recovery and any sequela; what specific tests and/or treatment may have been required and their results; for a fatal outcome, cause of death and a comment on its possible relationship to the suspected reaction should be provided. Any autopsy or other post-mortem findings (including a coroner’s report) should also be provided when available. Other information: anything relevant to facilitate assessment of the case, such as medical history, including allergy, drug or alcohol abuse; family history; findings from special investigations.

5. Details on Reporter of Event (Suspected ADR):
   • Name,
   • Address,
   • Telephone number,
   • Profession (specialty).

6. Administrative and Sponsor/Company Details:
   • Source of report: was it spontaneous, from a clinical investigation (provide details), from the literature (provide copy), other?
   • Date event report was first received by sponsor/manufacturer,
   • Country in which event occurred,
   • Type of report filed to authorities: initial or followup (first, second, etc.).
   • Name and address of sponsor/manufacturer/company,
   • Name, address, telephone number, and FAX number of contact person in reporting company or institution,
   • Identifying regulatory code or number for marketing authorization dossier or clinical investigation process for the suspected product (for example, IND or CTX number, NDA number).
   • Sponsor/manufacturer’s identification number for the case. (This number should be the same for the initial and followup reports on the same case.)


William B. Schultz,
Deputy Commissioner for Policy.
[FR Doc. 95–4961 Filed 2–28–95; 8:45 am]